HepaRegeniX

Financial Services · Biotechnology
Lately:6 news stories in 90 daysFollow changes →

Facts

as of Nov 17, 2026

Science HepaRegeniX aims at curing liver diseases by reversing the disease path through liver regeneration.

Founded
2016
Website
heparegenix.com

These are the key facts about HepaRegeniX on Alion as of Nov 17, 2026. It was founded in 2016. It has raised $39.4M in 2 funding rounds. The latest round is Venture - Series Unknown of $23.2M, announced in 2025.

Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake

What the registers and the postings say about this employer.

Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices

Financials

Funding rounds, investors and revenue on record.

$39.4MTotal raised
Venture - Series UnknownLatest round
2Rounds and grants
Money by yearUSD, rounds and grants
2025$23.2M1 record
2024$16.2M1 record
Largest rounds and grants
Sources: funding announcements, grant and company registers

Milestones

Apr 15, 2025
Jul 10, 2024
Raised a round Series C $16.2M
2016
Founded
Each milestone is dated by its source: registers, filings, the press

Newsroom

Sep 222026
News · markets.businessinsider.com
HepaRegeniX to seamlessly advance darizmetinib's clinical development to Phase 2a following completion of the Phase 1b in 2026Tuebingen, Germany, ...
Aug 262026
News · markets.businessinsider.com
U.S. FDA Orphan Drug Designation underscores darizmetinib's potential to address a significant unmet need following liver resection Tuebingen, Ger...
May 132026
Blog
Tuebingen, Germany, May 13, 2026 - HepaRegeniX GmbH ("HepaRegeniX"), a clinical-stage biotech company advancing novel therapies for acute and chronic liver diseases, announces th…
Feb 112026
Blog
Tuebingen, Germany, February 11, 2026 - HepaRegeniX GmbH ("HepaRegeniX"), a clinical-stage biotech company advancing novel therapies for acute and chronic liver diseases, today a…
Jun 10, 20252025
Blog
Tuebingen, Germany, June 10, 2025 - HepaRegeniX GmbH ("HepaRegeniX"), a clinical-stage company advancing novel therapies to treat acute and chronic liver disease, today announced…
Sources: the outlets named on each headline, each story once